Researchers receive grant from DTRA to support search for B. pseudomallei vaccine

February 1, 2017 --

Drs. Herbert Schweizer and Apichai Tuanyok are partnering with CUBRC, a medical biotechnology firm, and EpiVax, a pharmaceutical company, to develop a vaccine to protect against Burkholderia pseudomallei infection. B. pseudomallei is the species of bacteria that causes melioidosis, a potentially deadly disease most prevalent in Southeast Asia and northern Australia.

The group has received a four-year, $1.87 million grant from the Defense Threat Reduction Agency, and hope to learn more about how B. pseudomallei bacteria evade the immune system.

Visit the webpages below for more information about the project: 

http://www.epivax.com/news/1-87m-biodefense-grant-to-epivax-and-cubrc/

http://pbn.com/EpiVax-part-of-team-to-develop-vaccine-for-tropical-disease-classified-biothreat,119256?

http://pbn.com/EpiVax-part-of-team-to-develop-vaccine-for-tropical-disease-classified-biothreat,119256?